欢迎您访问中乔新舟官网!400-038-9959我的购物车(0)
您当前的位置:首页 > 产品中心
HuH-28人胆管癌细胞 (STR鉴定)
英文名:HuH-28
货号:ZQ1030
价格:¥7800.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

HuH-28人胆管癌细胞 (STR鉴定)

¥7800.00
+

HuH-28人胆管癌细胞专用培养基

¥350.00 ¥480.00

配套完培,省时省力,单买细胞无优惠

=

细胞套餐惊爆价

¥8150 ¥8280.00
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

HuH-28人胆管癌细胞

货号

ZQ1030

产品介绍

HuH-28是一种人肝脏胆管癌细胞系,它在胆管癌(Cholangiocarcinoma)的研究中被广泛使用。胆管癌是一种发生在胆管上皮细胞的恶性肿瘤,通常分为肝内胆管癌和肝外胆管癌。该细胞系可以用于CXCL7促进胆管癌细胞的增殖和侵袭的研究。通过RT-PCR分析、免疫印迹试验、酶联免疫吸附试验(ELISA)、MTT试验和Transwell试验等方法,可以检测HuH-28人胆管癌细胞系细胞增殖和侵袭性。

HuH-28细胞系在胆管癌研究中的应用中不限于以下几个方面:药物筛选、肿瘤发生机制的研究、抗肿瘤药物的筛选和评价、肿瘤免疫治疗的研究、基因表达和信号通路研究、肿瘤干细胞特性研究、肝胆系统肿瘤药物基因组学研究、胆管癌胞外囊泡circRNA研究等。这些应用场景展示了HuH-28细胞系在胆管癌研究中的多样性和重要性,为胆管癌的基础研究和临床治疗提供了重要的实验模型和研究工具。

种属

性别/年龄

/37岁

组织

疾病

肝癌

细胞类型

肿瘤细胞

形态学

上皮的

生长方式

贴壁

倍增时间

~80 hours (PubMed=2852388); ~1 week (Note=Lot 09082006), ~88 hours (Note=Lot 01062011), 55-128 hours (Note=Lot 07222016), 5 days (Note=Lot 10022018) (JCRB=JCRB0426)

培养基和添加剂

RPMI-1640(品牌:中乔新舟 货号:ZQ-200+10%胎牛血清(中乔新舟  货号:ZQ500-A+1%双抗(中乔新舟  货号:CSP006

推荐完全培养基货号

ZM1030

培养条件

95%空气,5%二氧化碳;37℃

STR位点信息

Amelogenin :X

CSF1PO 9,12

D2S1338 19

D3S1358 15,16

D5S818 9,12

D7S820 10 (RCB=RCB1943)

             :10,11 (JCRB=JCRB0426; PubMed=25877200; TKG=TKG 0438)

D8S1179 11

D13S317 9,12

D16S539 9

D18S51 15

D19S433 13,14.2

D21S11 30,33.2

FGA 23

Penta D 9,10

Penta E 13,22

TH01 9

TPOX 8

vWA 17

生物安全等级

 BSL-1

保藏机构

JCRB; JCRB0426;RCB; RCB1943

供应限制

仅供科研使用


货号

ZQ1030

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用

PubMed=2852388; DOI=10.1007/BF01851205
Kusaka Y., Tokiwa T., Sato J.
Establishment and characterization of a cell line from a human cholangiocellular carcinoma.
Res. Exp. Med. (Berl.) 188:367-375(1988)


PubMed=2856443
Kusaka Y., Muraoka A., Tokiwa T., Sato J.
Establishment and characterization of a human cholangiocellular carcinoma cell line.
Hum. Cell 1:92-94(1988)


PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)


PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)


PubMed=21451941; DOI=10.1007/s00534-011-0376-7
Sato J., Kimura T., Saito T., Anazawa T., Kenjo A., Sato Y., Tsuchiya T., Gotoh M.
Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
J. Hepatobiliary Pancreat. Sci. 18:700-711(2011)


PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)



CLPUB00275

Zach S., Birgin E., Ruckert F.
Primary cholangiocellular carcinoma cell lines.
J. Stem Cell Res. Transplant. 2:1013-1013(2015)



PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)


PubMed=26956050; DOI=10.18632/oncotarget.7914
Ding X.-W., Chaiteerakij R., Moser C.D., Shaleh H.M., Boakye J., Chen G., Ndzengue A., Li Y., Zhou Y.-L., Huang S.-B., Sinicrope F.A., Zou X.-P., Thomas M.B., Smith C.D., Roberts L.R.
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Oncotarget 7:20080-20092(2016)


PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442
Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C., Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K., Greninger P., McDermott U., Garnett M.J., Jenkins R.L., Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y., Goyal L., Ferrone C.R., Zhu A.X., Joung J.K., Shokat K.M., Benes C.H., El-Bardeesy N.
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.
Cancer Discov. 6:727-739(2016)


PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)


PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)


PubMed=31077409; DOI=10.1002/hep.30704
Sittithumcharee G., Suppramote O., Vaeteewoottacharn K., Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M., Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K., Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P., Pairojkul C., Wongkham S., Sampattavanich S., Okada S., Jirawatnotai S.
Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity.
Hepatology 70:1614-1630(2019)

暂无相关产品!
公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
           上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经...
联系我们 / Contact
电 话:021-56760357;021-56760351
传 真:
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved.
技术支持:中乔新舟沪ICP备14008091号